Clinical prediction rule

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

Retrieved on: 
Thursday, June 2, 2022
Clinical prediction rule, VTE, INR, CHF, D-dimer, Pharmacy, Research, School, Heart, RSV, Deep vein thrombosis, Annual report, Health care, Platform, Security (finance), Disease, CE, Electric Bond and Share Company v. Securities and Exchange Commission, Solution, Multimedia, Heart failure, Physician, CRP, N-terminal prohormone of brain natriuretic peptide, Peptide, Risk, Patient, Pulmonary embolism, Glycated hemoglobin, DVT, Diabetes, Laboratory, Private Securities Litigation Reform Act, Infection, COVID-19, Thrombosis, Diagnosis, SEC, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Ambulatory, POC, Emergency, Health, View, Medical device, Pharmaceutical industry

The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.

Key Points: 
  • The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.
  • D-Dimer testing is widely accepted as the first step in the management of patients suspected of VTE.
  • LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.
  • In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

Retrieved on: 
Thursday, June 2, 2022
Clinical prediction rule, VTE, INR, CHF, D-dimer, Pharmacy, Research, School, Heart, RSV, Deep vein thrombosis, Annual report, Health care, Platform, Security (finance), Disease, CE, Electric Bond and Share Company v. Securities and Exchange Commission, Solution, Heart failure, Physician, CRP, N-terminal prohormone of brain natriuretic peptide, Peptide, Risk, Patient, Pulmonary embolism, Glycated hemoglobin, DVT, Diabetes, Laboratory, Private Securities Litigation Reform Act, Infection, COVID-19, Thrombosis, Diagnosis, SEC, Severe acute respiratory syndrome coronavirus 2, Degenerative disease, Ambulatory, POC, Emergency, Health, Medical device, Pharmaceutical industry

The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.

Key Points: 
  • The LumiraDx NT-proBNPand the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test.
  • D-Dimer testing is widely accepted as the first step in the management of patients suspected of VTE.
  • LumiraDx has, on the market and in development, 30+ tests covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, all on the LumiraDx Platform.
  • In addition, LumiraDx has a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions from the lab to point of need.

Exactech Presents Award-Winning Clinical Research at 2022 Orthopaedic Research Society Annual Meeting

Retrieved on: 
Friday, February 11, 2022
Research, Technology, Medical Devices, Surgery, Other Technology, Clinical Trials, Other Health, Biotechnology, Health, Science, Newton, Instagram, Algorithm, Patient, Surgeon, Percussion section, ORS, Motion, Journal, YouTube, Western University, MCID, SCB, Active, Elbow, Diagnosis, Bias, Machine learning, Decision-making, Clinical prediction rule, Ligamentous laxity, LinkedIn, Twitter, PASS, Hospital, Partnership, Physician, Research, Multimedia, Investment, Maxima and minima, Dentistry, Medical imaging, Medical device, Wood drying, Silviculture, Pacific Ocean, Shoulder

Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today that eight studies featuring new scientific and clinical research were presented at the 2022 Orthopaedic Research Society (ORS) annual meeting, on Feb. 4-8 in Tampa, Fla.

Key Points: 
  • Exactech, a developer and producer of innovative implants, instrumentation and smart technologies for joint replacement surgery, announced today that eight studies featuring new scientific and clinical research were presented at the 2022 Orthopaedic Research Society (ORS) annual meeting, on Feb. 4-8 in Tampa, Fla.
  • View the full release here: https://www.businesswire.com/news/home/20220211005346/en/
    Exactech Presents Award-Winning Clinical Research at 2022 Orthopaedic Research Society Annual Meeting (Photo: Business Wire)
    Three studies, each of which used machine learning to predict outcomes after shoulder arthroplasty, were nominated for awards.
  • Data from this research came from a multinational patient outcomes database drawn from more than a decade of active clinical collection efforts, which provides the engineering/development and clinical research teams, along with worldwide clinical collaborators, robust information to assess the performance of Exactech products.
  • Other presented research established new thresholds for patient satisfaction-based improvement after shoulder arthroplasty5 and demonstrated positive clinical and radiographic outcomes using the Equinoxe Preserve humeral stem6.